Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibito

专利摘要:
The present invention provides a combination of cardiovascular therapeutic compounds for the prevention and treatment of cardiovascular diseases including hypercholesterolemia, atherosclerosis or hyperlipidemia. The disclosed combination includes a venous bile acid transport inhibitor mixed with a cholesteryl ester transfer protein (CETP) inhibitor.
公开号:KR20010108046A
申请号:KR1020017008085
申请日:1999-12-17
公开日:2001-12-07
发明作者:켈러브래들리티；시코르스키제임스에이；글렌케빈씨；코놀리다니엘티；스미스마아크이；슈조셉알
申请人:윌리암스 로저 에이；지.디. 썰 엘엘씨；
IPC主号:

专利说明:

FIELD OF THE INVENTION [0001] The present invention relates to a combination of a cholanic acid transport inhibitor and a cholesteryl ester transport protein inhibitor for the indication of cardiovascular diseases. The present invention relates to a combination of a cholanic acid transport inhibitor and a cholesteryl ester transport protein inhibitor,
[3] It is well known that hyperlipidemia associated with elevated total cholesterol and low density lipoprotein (LDL) cholesterol levels is a major risk factor for coronary heart disease, particularly atherosclerosis. Since high LDL cholesterol levels increase the risk of atherosclerosis, methods of lowering plasma LDL cholesterol will be therapeutically effective in the treatment of atherosclerosis and other diseases associated with accumulation of vascular lipids. These diseases include, but are not limited to, coronary heart disease, peripheral vascular disease and diaphoresis.
[4] Atherosclerosis is present in most coronary artery disease (CAD), which is the leading cause of morbidity and mortality in modern society. High LDL cholesterol levels (greater than about 180 mg / dl) and low HDL cholesterol levels (less than 35 mg / dl) have been found to contribute significantly to the development of atherosclerosis. The reverse HDL / LDL ratio negatively affects other diseases or risk factors such as peripheral vascular disease, diaphoresis and hypercholesterolemia.
[5] It has been found that interfering with the recycling of bile acids from the intestinal lumen reduces the serum cholesterol levels that are causally related. Pneumochemical data have been accumulated indicating that these decreases mean improved disease state of arteriosclerosis. Biochemistry, physiology and known agonists related to bile acids and cholesterol are described in Stedronsky's article "Interaction of bile acids and cholesterol with nonsystemic agents having hypocholesterolemic properties," Biochimica et Biophysica Acta , 1210 , 255-287 (1994) Are discussed.
[6] As reported by Heubi, JE et al., Transient pathological changes have been shown to be consistent with intermittent circulatory arrest (obstruction) of bile acids in humans with congenital IBAT deficiency deficiency. Primary Bile Acid Malabsorption: Defective in Vitro Ileal Active Bile Acid Transport ", Gastroenterology , 83 , 804-11 (1982).
[7] In another approach to reducing the recycling of bile acids, the venous bile acid transit system is estimated as a pharmaceutical target for the treatment of hypercholesterolemia, based on the interruption of the intestinal circulation by a specific transport inhibitor [Kramer, et al., &Quot; Intestinal Bile Acid Absorption " The Journal of Biological Chemistry , 268 (24), 18035-46 (1993)].
[8] In several patent applications, the Stroke Aktiengesellschaft discloses polymers and derivatives thereof of various naturally occurring constituents of the long-circulatory system, including bile acids, which inhibit the transport of physiological bile acids and ultimately the drug, Especially as a hypocholesterolemic drug, to a level that is sufficiently effective to reduce LDL cholesterol. Each of the patent applications for a stroke, which discloses compounds inhibiting such bile acid transport, is shown below.
[9] R1. Canadian Patent Application 2,025,294
[10] R2. Canadian patent application 2,078,588
[11] R3. Canadian patent application 2,085,782
[12] R4. Canadian patent application 2,085,830
[13] R5. EP application 0 379 161
[14] R6. EP Application 0 549 967
[15] R7. EP application 0 559 064
[16] R8. EP application 0 563 731
[17] Fatty acid metabolism and coronary vascular disease are disclosed in International Patent Application No. WO 93/321146.
[18] Other selected benzothiepines are known for their use as hypolipidemic and hypocholesterolemic agents, particularly for the treatment or prevention of atherosclerosis, such as that disclosed in application EP 508425. French patent application FR 2661676 discloses additional benzothiepines for use as hypolipidemic and hypocholesterolemic agents. In addition, patent application WO 92/18462 presents other benzothiepines for use as hypolipidemic and hypocholesterolemic agents. See U.S. Patent No. 5,994,391 (Lee et al.). Each of the benzothiophene hypolipidemic and hypocholesterolemic agents disclosed in each of these patent applications is limited by an amide bonded to the carbon adjacent to the phenyl ring of the fused bicyclobenzothiepine ring.
[19] Another benzothiepine useful in the treatment of hypercholesterolemia and hyperlipidemia is disclosed in patent application PCT / US95 / 10863. Additional benzothiepines useful in the treatment and prevention of hypercholesterolemia and hyperlipidemia and pharmaceutical compositions of such benzothiepines are described in PCT / US97 / 04076. Other benzothiepines useful for the treatment and prevention of hypercholesterolemia and hyperlipidemia and compositions thereof are described in U.S. Patent Application No. 08 / 816,065.
[20] Inhibition of bile acid transport in vitro has been disclosed in relation to hypolipidemic activity in the patent application WO 93/16055 entitled " Hypolipidemic Benzothiazepine Compounds of Welcombe Foundation ". This publication discloses a number of hypolipidemic benzothiazepine compounds. Additional hypolipidemic benzothiazepine compounds, particularly 2,3,4,5-tetrahydrobenzo-1-thi-4-azepine compounds, are disclosed in patent application WO 96/05188. Particularly useful benzothiazepines disclosed in WO 96/05188 are those represented by the formula B-2. Additional hypolipidemic benzothiazepine compounds are described in patent application WO 96/16051.
[21]
[22] (3R, 5R) -3-butyl-3-ethyl-2,3,4,5-tetrahydro-7,8-dimethoxy-5-phenyl-l- 4- benzothiazepine 1,1-
[23] Other benzothiazepine compounds useful for the control of cholesterol are described in PCT international patent application WO 99/35135. This includes the compound represented by the formula (B-7).
[24]
[25] Other IBAT inhibitor compounds are T. T. Ichihashi et al ., J. Pharmacol. Exp. Ther ., 284 (1), 43-50 (1998). Of these classes of compounds, S-8921 (methyl 1- (3,4-dimethoxyphenyl) -3- (3-ethylvaleryl) -4- hydroxy- Naphthoate) are particularly useful. And other naphthalene compounds or lignin derivatives useful for the treatment or prevention of lipidemia or atherosclerosis are described in PCT patent application WO 94/24087.
[26]
[27] Inhibition of cholesteryl ester transport protein (CETP) has been shown to effectively modulate the plasma HDL / LDL ratio and is expected to inhibit the progression and / or formation of certain cardiovascular diseases. CETP is a plasma protein that promotes the migration of cholesteryl esters and triglycerides between various lipoproteins in the blood (Tall, J. Lipid Res., 34 , 1255-74 (1993)). When CETP moves cholesteryl ester from HDL to LDL, it has the effect of lowering HDL cholesterol. Thus, inhibition of CETP increases plasma HDL cholesterol and lowers plasma LDL cholesterol, thereby providing a therapeutically beneficial plasma lipid profile. Evidence for this effect is reported in McCarthy, Medicinal Res. Revs ., 13 , 139-59 (1993). Further evidence of this effect can be found in Sitori, Pharmac . Ther ., 67 , 443-47 (1995). This phenomenon was first demonstrated by Swenson et al. Using monoclonal antibodies that specifically inhibit CETP ( J. Biol. Chem ., 264, 14318 (1989)]. In rabbits, the antibodies raised plasma HDL cholesterol and decreased LDL cholesterol. Son, etc. [ Biochim . Biophys. Acta , 795 , 743-480 (1984) describe proteins derived from human plasma that inhibit CETP. U.S. Pat. No. 5,519,001, which is incorporated herein by reference, describes peptides consisting of 36 amino acids derived from non-apo C-1 that have been issued to Kushwaha et al. And inhibit CETP activity. Cho et al. [Biochim. Biophys. Acta 1391, 133-144 (1998) describe peptides derived from porcine plasma inhibiting human CETP. Bonin et al. [J. Peptide Res., 51, 216-225 (1998)) discloses decapeptide inhibitors of CETP. Hedge et al., Bioorg. Med. Chem. Lett, 8, 1277-80 (1998)) discloses a depspeptide fungal metabolite as a CETP inhibitor.
[28] There are several reports of non-peptide compounds acting as CETP inhibitors. Barrett et al ., J. Am. Chem. Soc. , 188 , 7863-63 (1996) describe cyclopropane-containing CETP inhibitors. Furthermore, cyclopropane-containing CETP inhibitors have been described by Kuo et al ., J. Am. Chem. Soc. , 117 , 10629-34 (1995). Pietzonka et al . [ Bioorg. Med. Chem. Lett. , 6 , 1951-54 (1996)) describe phosphonate-containing analogues of cholesteryl esters as CETP inhibitors. Coval et al., Bioorg. Med. Chem. Lett., 5, 605-610 (1995) describe Wiedendiol-A and B and related sesquiterpene compounds as CETP inhibitors. Lee et al. [ J. Antibiotics , 49 , 693-96 (1996)] describe CETP inhibitors derived from insect fungi. Busch et al. ( Lipids , 25 , 216-220, 1990) describe cholesteryl acetyl bromide as a CETP inhibitor. Morton and Zilversmit [ J. Lipid Res. , 35 , 836-47 (1982)) discloses that p-chloromercuriphenylsulfonate, p-hydroxymercuribenzoate and ethylmercury thiosalicylate inhibit CETP. Connolly et al. [ Biochem, Biophys. Res. Comm. , 223 , 42-47 (1996) describe other cysteine modifiers as CETP inhibitors. Xia et al. Describe 1,3,5-triazine as a CETP inhibitor [Bioorg. Med. Chem. Lett., 6, 919-22 (1996)). Bisgaier et al. [ Lipid , 29 , 811-8 (1994)] describe 4-phenyl-5-tridecyl-4H-1,2,4-triazole-thiol as a CETP inhibitor. Additional triazole CETP inhibitors are described in United States Patent Application Serial No. 09 / 153,360, which is incorporated herein by reference. Sikorski et al. Describe another novel CETP inhibitor in PCT patent application WO 9914204.
[29] Substituted 2-mercaptoaniline compounds can be used as CETP inhibitors, Is described in PCT patent application WO 98/35937 by H. Shinkai et al.
[30] Some substituted heteroalkylamine compounds are known as CETP inhibitors. In European Patent Application No. 796846, Schmidt et al. Describe 2-aryl-substituted pyridines as cholesterol ester transport protein inhibitors useful as cardiovascular agents. The substituent at C ₃ in the pyridine ring may be a hydroxyalkyl group. In European Patent Application No. 801060, Dow and Wright describe heterocyclyl derivatives substituted with an aldehyde addition product of an alkylamine to provide 1-hydroxy-1-amine. They report on 3-adrenergic receptor agonists useful for treating diabetes and other disorders. In British Patent Application No. 2305665, Fisher et al. Describe 3-agonist secondary amino alcohol substituted pyridine derivatives useful for treating several disorders including cholesterol levels and atherosclerotic diseases. In European Patent Application No. 818448 (incorporated herein), Schmidt et al. Describe tetrahydroquinoline derivatives as cholesterol ester transport protein inhibitors. Schmek et al. In European Patent Application No. 818197 describes pyridine having a fused heterocycle as a cholesterol ester transport protein inhibitor. Brandes et al. In German Patent Application No. 19627430 describe bicyclic condensed pyridine derivatives as cholesterol ester transport protein inhibitors. In PCT patent application WO 9839299, Muller-Gliemann et al. Describe quinoline derivatives as cholesterol ester transport protein inhibitors.
[31] In addition, polycyclic compounds that are useful as CETP inhibitors are also known in the art. And Japanese Patent No. 10287662 by A. Oomura et al. For example, therapeutic compounds having structures C-1 and C-8 were prepared by culturing Penicillium spp.
[32] Cycloalkylpyridines useful as CETP inhibitors are described in European Patent EP 818448 by Schmidt et al. For example, therapeutic compounds having the structure C-9 are described as being particularly effective as CETP inhibitors.
[33] Substituted tetrahydronaphthalene compounds useful as CETP inhibitors are disclosed in PCT patent application WO 9914174. This includes the use of (8S) -3-cyclopentyl-1- (4-fluorophenyl) -2 - [(S) -fluoro (4- trifluoromethylphenyl) methyl] -8- Spirocobutyl-5,6,7,8-tetrahydronaphthalene. ≪ / RTI >
[34] Several 4-heteroaryl-tetrahydroquinolines useful as CETP inhibitors are described in PCT patent application WO 9914215. For example, 3- (4-trifluoromethylbenzoyl) -5,6,7,8-tetrahydroquinolin-5-one has been described herein as a useful CETP inhibitor.
[35] Several combinations of therapies for the treatment of cardiovascular diseases are described in the paper. A combination of an HMG CoA reductase inhibitor and an IBAT inhibitor useful in the treatment of cardiovascular disease is described in U.S. Patent Application No. 09 / 037,308.
[36] Combination therapy of fluvastatin and nisartrol is described in J. Sasaki et al. (Sangdong). The researchers conclude that the combination of nisartrol and fluvastatin does not "seem to increase or attenuate the beneficial effects of fluvastatin at the 750 mg / day dose."
[37] L. Cashin-Hemphill et al. [J. Am. Med. Assoc., 264 (23), 3013-17 (1990)] describe the beneficial effects of the combination of cholestypol and niacin in coronary atherosclerosis. This effect includes non-progression and degeneration of natural coronary artery lesions.
[38] The combination therapy of acipimox and simvastatin has an advantageous HDL effect in patients with high triglyceride levels (N. Hoogerbrugge et al., J. Internal Med., 241 , 151-55 (1997)).
[39] Combination therapy of cystostanol ester margarine and pravastatin is described in H. Gylling et al. Lipid Res., 37 , 1776-85 (1996). This therapy has been reported to inhibit cholesterol absorption and significantly reduce LDL cholesterol in patients with insulin-independent diabetes mellitus.
[40] Brown et al., New Eng. J. Med., 323 (19), 1289-1339 (1990)] describe the combination therapy of colestipol and lovastatin, which reduces the progression of atherosclerotic lesions and increases lesion degeneration compared to lovastatin alone.
[41] The combination therapy of apoB secretion inhibitor and CETP inhibitor is described in Chang et al. in PCT patent application WO 9823593.
[42] Bush et al., PCT patent application WO 99/11263, includes statins and amlodipine to treat subjects suffering from angina, atherosclerosis, complications of hypertension and hyperlipidemia, and to treat symptoms of heart rate arrest And the like. Bush et al. Describe the combination therapy of amlodipine and atorvastatin in the above patent application.
[43] Scott et al., PCT patent application WO 99/11260, describes a combination therapy comprising a hypertension therapeutic and atorvastatin.
[44] British patent application GB 2329334 to Dettmar and Gibson claims a therapeutic composition useful for lowering plasma low density lipoprotein and cholesterol levels. The composition comprises a bile acid complex and an HMG CoA reductase inhibitor.
[45] These references show a continuing need to find safe and effective drugs for the treatment or prevention of cardiovascular diseases.
[1] This application claims priority to U.S. Provisional Application No. 60 / 113,955, filed Dec. 23, 1998, and U.S. Provisional Application No. 60 / 143,043, filed July 7, 1999.
[2] The present invention relates to a method for treating cardiovascular diseases, and more particularly, to a combination therapy, composition and medicament for prevention and treatment of hyperlipidemia such as atherosclerosis, hypercholesterolemia and other coronary artery diseases of mammals And their use. More specifically, the present invention relates to an ileal bile acid transporter (IBAT) inhibitory compound. The present invention also relates to cholesteryl ester transfer protein (CETP) activity inhibitory compounds.
[46] Summary of the Invention
[47] In order to address the ongoing need to find safe and effective drugs for the prevention and treatment of cardiovascular diseases, there is currently reported a combination therapy of cardiovascular drugs.
[48] Among several embodiments, the present invention provides a combination therapy comprising the use of a first amount of an IBAT inhibitor and another cardiovascular therapeutic agent useful for the treatment or prevention of a second amount of hyperlipidemia, atherosclerosis or hypercholesterolemia . Wherein said first and second amounts together comprise an amount effective for an anti-hyperlipidemic condition, an amount effective for an anti-atherosclerotic condition or an amount effective for an anti-hypercholesterolemic condition. For example, one of the many embodiments of the present invention is a combination therapy comprising a therapeutic dose of an IBAT inhibitor and a CETP inhibitor. A preferred embodiment of the present invention is a combination therapy comprising a therapeutic dose of a benzothiophene IBAT inhibitor and a CETP inhibitor.
[49] Other embodiments of the invention include the use of any of the cardiovascular combination therapies described herein for the treatment or prevention of hypercholesterolemia, atherosclerosis or hyperlipidemia. Thus, in one embodiment, the invention provides a method of treating or preventing a hyperlipidemic condition comprising administering a combination of a unit dosage form containing a first amount of a venous bile acid transport inhibiting compound and a second amount of a CETP inhibiting compound Wherein the method comprises the steps of: Wherein the first and second amounts together comprise an amount effective for the anti-lipidemic state of the compound.
[50] In another embodiment, the invention provides a method for treating or preventing atherosclerosis, comprising administering to a patient in need thereof a combination of a unit dosage form containing a first amount of a venous bile acid transport inhibiting compound and a second amount of a CETP inhibiting compound A method for the treatment or prevention of atherosclerotic disease conditions. Wherein the first and second amounts together comprise an amount effective for the anti-atherosclerotic condition of the compound.
[51] In another embodiment, the invention provides a method of treating or preventing hypercholesterolemia comprising administering to a patient in need thereof a combination of a unit dosage form containing a first amount of a venous bile acid transport inhibiting compound and a second amount of a CETP inhibitor And a method for the treatment or prevention of hypercholesterolemia. Wherein the first amount and the second amount together comprise an amount effective for the anti-hypercholesterolemia of the compound.
[52] The scope of applicability of the present invention will be apparent from the following detailed description. It should be understood, however, that the detailed description and the examples below illustrate preferred embodiments of the invention but are provided for illustrative purposes only and that various changes and modifications without departing from the spirit of the invention will be apparent to those skilled in the art upon reading the detailed description of the invention something to do.
[53] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[54] The following detailed description is provided to aid those skilled in the art in practicing the invention. In addition, this specification should not be construed as unduly limiting the invention, as modifications and variations of the embodiments discussed herein may be made by those skilled in the art without departing from the scope or spirit of the invention disclosed herein.
[55] The contents of each of the references cited herein, including the contents of the references cited in these main references, are incorporated herein by reference in their entirety.
[56] a. Justice
[57] The following definitions are provided to assist the reader in reading the detailed description of the invention:
[58] &Quot; Placebo bile acid transporter " or " IBAT " is synonymous with the normal sodium co-dependent bile acid transporter or ASBT.
[59] &Quot; Benzothiepin IBAT inhibitor " refers to a venous bile acid transport inhibitor comprising a therapeutic compound having a 2,3,4,5-tetrahydro-1-benzothiepine 1,1-dioxide structure.
[60] The term " CETP inhibitor " or " CETP inhibiting compound " as used herein refers to any therapeutic compound derived from a chemical or biological source that inhibits cholesteryl ester transfer protein activity.
[61] &Quot; Combination therapy " refers to the administration of two or more therapeutic agents for the treatment of hyperlipidemia conditions, such as atherosclerosis and hypercholesterolemia. Such administration includes single or multiple administrations of these therapeutic agents, such as multiple, divided dosage forms, for each inhibitor, with a defined ratio of active ingredients. Such administration also includes the sequential use of each type of therapeutic agent. In any case, the therapy will provide beneficial effects of drug combination in treating hyperlipidemic conditions.
[62] The term " therapeutically effective " means that the amount of the therapeutic agent in the combination therapy is appropriate. This amount of mixing will achieve the purpose of reducing or eliminating hyperlipidemia.
[63] &Quot; Therapeutic compound " means a compound useful in the treatment or prevention of a hyperlipidemic condition, including atherosclerosis and hypercholesterolemia.
[64] b. Combination
[65] Combinations of the present invention will have a number of uses. For example, the individual doses of therapeutic compounds used in the combinations of the invention through dose adjustment and medical observation will be lower than the typical doses of therapeutic compounds used in monotherapy. Lowered doses will offer advantages such as reduced side effects of individual therapeutic compounds when compared to single therapies. In addition, combination therapies with lower side effects in comparison to single therapies will lead to greater patient co-operation for therapy.
[66] Another use of the invention is in the form of a combination having a complementary effect or a complementary mode of action. For example, IBAT inhibitors regulate serum cholesterol levels by preventing bile acid reabsorption into the ileum. In contrast, CETP inhibitors interfere with the transfer of cholesteryl esters and triglycerides between various lipoproteins in the blood.
[67] Compounds useful in the present invention include a wide variety of therapeutic compounds. Some IBAT inhibitors useful in the present invention are disclosed in patent application PCT / US95 / 10863, which is incorporated herein by reference. More IBAT inhibitors are disclosed in patent application PCT / US97 / 04076, which is incorporated herein by reference. Other IBAT inhibitors useful in the present invention are disclosed in U.S. Serial No. 08 / 816,065, which is incorporated herein by reference. Further IBAT inhibitor compounds useful in the present invention are disclosed in WO 98/40375, which is incorporated herein by reference. Additional IBAT inhibitor compounds useful in the present invention are disclosed in U.S. Serial No. 08 / 816,065, which is incorporated herein by reference. IBAT inhibitory compounds useful in the present invention are disclosed in U.S. Patent No. 5,994,391, which is incorporated herein by reference. IBAT inhibitors of particular interest in the present invention include diastereomers, enantiomers, racemates, salts and tautomers of the IBAT inhibitors of Table 1 as well as those shown in Table 1 .
[68] [ Table 1 ]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83] Several individual CETP inhibitor compounds useful in the present invention are disclosed separately in each of the following patent applications, the disclosures of which are incorporated herein by reference.
[84] R9. U. S. Patent Application Serial No. 60/101661.
[85] R10. U. S. Patent Application Serial No. 60/101711.
[86] R11. U.S. Patent Application Serial No. 60/101660.
[87] R12. U.S. Patent Application Serial No. 60/101664.
[88] R13. U.S. Patent Application Serial No. 60/101668.
[89] R14. U. S. Patent Application Serial No. 60/101662.
[90] R15. U. S. Patent Application Serial No. 60/101663.
[91] R16. U. S. Patent Application Serial No. 60/101669.
[92] R17. U. S. Patent Application Serial No. 60/101667.
[93] R18. U. S. Patent Application Serial No. 09 / 401,916.
[94] R19. U. S. Patent Application Serial No. 09 / 405,524.
[95] R20. United States Patent Application Serial No. 09 / 404,638.
[96] R21. United States Patent Application Serial No. 09 / 404,638.
[97] R22. U.S. Patent Application Serial No. 09 / 400,915.
[98] R23. U.S. Patent No. 5,932,587.
[99] R24. U.S. Patent No. 5,925,645.
[100] CETP inhibitor compounds of particular interest in the present invention include diastereoisomers, enantiomers, racemates, salts and tautomers of the CETP inhibitors of Table 2, as well as those shown in Table 2.
[101] [ Table 2 ]
[102]
[103]
[104]
[105]
[106]
[107]
[108] Compounds useful in the present invention (e. G., Ileal bile acid transport inhibiting compounds or CETP inhibiting compounds) may have no asymmetric carbon atoms, or alternatively useful compounds may have one or more asymmetric carbon atoms. If a useful compound has more than one asymmetric carbon atom, both racemates and stereoisomers, such as diastereoisomers and enantiomers, are both included in pure form and as a mixture. Such stereoisomers can be prepared using conventional techniques, for example, by reacting starting materials that are enantiomers or isolating the isomers of the compounds of the present invention.
[109] Isomers can include geometric isomers, such as cis-isomers or trans-isomers for double bonds. All such isomers are among the compounds useful in the present invention.
[110] Compounds useful in the present invention also include tautomers.
[111] Compounds useful in the present invention as discussed below include their salts, solvates, and drug precursors.
[112] Dosage amount, dosage formulations and route of administration
[113] The compositions of the present invention may be administered in any manner, preferably orally, to prevent or treat a hyperlipidemic disease or condition whereby these compounds are administered in the body of a mammal (e.g., a human) For example, they may contact their active sites in the ileum, plasma or liver.
[114] To prevent or treat the above-mentioned diseases, compounds useful in the compositions and methods of the present invention may be used as the compound itself. Particularly pharmaceutically acceptable salts are particularly preferred for pharmaceutical applications because they are more soluble than the original compound. Such salts should certainly have a pharmaceutically acceptable anion or cation. If desired, the preferred pharmaceutically acceptable acid addition salts of the compounds of the present invention include inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid , Those derived from organic acids such as gluconic acid, glycolic acid, isothionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, toluenesulfonic acid, tartaric acid and trifluoroacetic acid. Chloride salts are particularly preferred for pharmaceutical purposes. Suitable pharmaceutically acceptable base salts include ammonium salts, alkali salts such as sodium salts and potassium salts, and alkaline earth salts such as magnesium salts and calcium salts.
[115] Anions useful in the present invention should also be pharmaceutically acceptable and selected from the list above.
[116] The compounds useful in the present invention may be provided with an acceptable carrier in the form of a pharmaceutical composition. The carrier should be acceptable in the sense of being compatible with the other ingredients of the composition and should not be harmful to the recipient. The carrier may be solid or liquid, or both, and is preferably formulated with the compound as a unit dosage form composition (e.g., tablet) which may contain from 0.05 to 95% by weight of the active compound. Other pharmaceutically active ingredients may be present including other compounds of the present invention. The pharmaceutical compositions of the present invention can be prepared by any well known pharmaceutical technique, and the technique consists primarily of mixing the ingredients.
[117] Optionally, the combination of the present invention may comprise a composition comprising an ileal bile acid transport inhibiting compound and a CETP inhibiting compound. In such compositions, ileal bile acid transport inhibiting compounds and CETP inhibiting compounds may be present in a single dosage form, for example, pills, capsules, or liquids containing both of these compounds.
[118] These compounds may be administered in any conventional manner, either as individual therapeutic compounds or in combination with pharmaceuticals as a combination of therapeutic compounds.
[119] The amount of compound required to achieve the desired biological effect depends, among other things, on a number of factors such as the particular compound selected, the intended use, the mode of administration and the clinical condition of the receptor.
[120] In general, the total daily dose of the IBAT inhibitor is about 0.01 to about 1000 mg / day, preferably about 0.1 to about 50 mg / day, most preferably about 1 to 10 mg / day.
[121] For CETP inhibitors, the daily dosage is about 0.01 to about 100 mg / kg body weight per day, preferably about 0.5 to about 20 mg / kg body weight per day.
[122] The daily doses described above for the various therapeutic compounds may be administered to the patient in a single dose or in a balanced multiple dose. When administered separately, it may be administered 2 to 6 times a day. The drug may be a sustained-release formulation effective to achieve the desired result.
[123] In the case of pharmaceutically acceptable salts, the indicated weight is regarded as an acid equivalent or base equivalent of the salt-derived therapeutic compound.
[124] Oral delivery of a combination of the present invention includes formulations well known in the art that provide sustained or sustained drug delivery to the gastrointestinal tract through any multi-action mechanism. These include pH-sensitive release from dosage, gentle erosion of tablets or capsules, retention in the stomach based on the physical properties of the formulation, biological attachment of the formulation to the mucosal lining of the intestinal tract, But are not limited to, enzymatic release of the active drug. In some cases of therapeutic compounds useful in the present invention (e.g., IBAT inhibitors or CETP inhibitors), the desired effect may be to prolong the period of delivery of the active drug molecule to the site of action (e.g., ileum) by manipulating the formulation have. Accordingly, controlled-release preparations of enteric coated and enteric coated form are within the scope of the present invention. Suitable enteric coatings include cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methacrylic acid methyl esters.
[125] Combinations of the present invention may be delivered orally in solid, semi-solid, or liquid form. For liquid or semi-solid forms, the combination of the present invention may be in the form of, for example, liquid, syrup, or a type contained in gel capsules (e.g., a gel lid). In one embodiment, when an IBAT inhibitor is used in the combination of the present invention, the IBAT inhibitor may be provided in a form contained in a liquid, syrup or gel capsule. In another embodiment, when a CETP inhibitor is used in the combination of the present invention, the CETP inhibitor may be provided in the form contained in a liquid, syrup or gel capsule.
[126] The dosage of any of these therapeutic compounds can conveniently be administered at an infusion rate of about 10 to 100 ng / kg body weight per minute. Suitable infusion liquids for this purpose may contain, for example, from about 0.1 ng / ml to about 10 mg / ml, preferably from about 1 ng / ml to about 10 mg / ml. The unit dosage form may contain, for example, from about 1 mg to about 10 g of a compound of the present invention. Thus, injectable ampoules may contain, for example, from about 1 mg to about 100 mg.
[127] The pharmaceutical compositions according to the invention include those suitable for oral, rectal, topical, buccal (e.g. sublingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal, intravenous) Will depend upon the nature and severity of the condition being treated and the nature of the particular compound employed. In most cases, the preferred route of administration is oral.
[128] Pharmaceutical compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, lozenges, or tablets, each of which may contain one or more therapeutic compounds useful in the present invention in powder or granules in predetermined amounts; With a solution or suspension of an aqueous or non-aqueous liquid; Or as an oil-in-water or water-in-oil emulsion. As indicated, such compositions may be prepared by any suitable method of the pharmaceutical system, which method comprises combining the active ingredient (s) and the carrier (which may constitute one or more accessory ingredients). In general, the compositions are prepared by uniformly mixing the liquid or finely divided solid carrier or both with the active compound uniformly and, if necessary, subsequently shaping the product. For example, tablets may be prepared by compressing or molding powder or granules of the compound, optionally together with one or more accessory ingredients. Compressed tablets may be prepared by compressing a compound of the free-flowing form (e.g., powder or granules) in a suitable machine, optionally with a binder, lubricant, inert diluent and / or surface active / dispersing agent (s). Molded tablets may be prepared by molding powdered compounds moistened with an inert liquid diluent in a suitable machine.
[129] Pharmaceutical compositions suitable for buccal (sublingual) administration may be prepared by incorporating the compounds of the present invention into a flavored base (usually sucrose) and rosin, including acacia or tragacanth, and inert bases such as gelatin and glycerin or sucrose and acacia Lt; RTI ID = 0.0 > pills. ≪ / RTI >
[130] Pharmaceutical compositions suitable for parenteral administration conveniently include sterile aqueous preparations of the compounds of the present invention. These agents are preferably administered intravenously, but may also be administered by subcutaneous, intramuscular, or intradermal injection. Such formulations may conveniently be prepared by mixing the compound with water and causing the resulting solution to become sterile and become isotonic with the blood. Injectable compositions according to the present invention will generally contain the compounds described herein at 0.1 to 5% w / w.
[131] Pharmaceutical compositions suitable for rectal administration are preferably provided as suppositories in unit dosage form. These may be prepared by mixing the compound of the present invention with one or more conventional solid carriers (e. G., Cocoa butter) and then shaping the resulting mixture.
[132] The pharmaceutical compositions suitable for topical application to the skin may preferably take the form of ointments, creams, lotions, pastes, gels, sprays, aerosols, or oils. Carriers which may be used include petroleum jelly (e.g., Vaseline), lanolin, polyethylene glycol, alcohol, and combinations of two or more thereof. The active compound is usually present in the composition in a concentration of 0.1 to 50% w / w, such as 0.5 to 2%.
[133] Percutaneous administration is also possible. Pharmaceutical compositions suitable for transdermal administration may be provided as a separate patch and the patch may be adapted for intimate contact with the epidermis of the receptor for extended periods of time. Such patches suitably contain the compounds of the present invention, which are optionally dissolved in a buffered aqueous solution and / or dispersed in an adhesive or dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably 3% to 15%. Potentially, in particular compounds can be delivered from patches by electrotransport or iontophoresis, examples of which are described in Pharmaceutical Research , 3 (6), 318 (1986) have.
[134] In any case, the amount of active ingredient that can be mixed with the carrier material for administration in a single dosage form will vary depending upon the host treated and the particular mode of administration.
[135] Solid dosage forms for oral administration include capsules, tablets, pills, powders, gel covers and granules as indicated above and may contain one or more inert diluents (e. G., Sucrose, lactose, or starch) Mixed. Such formulations may also contain additional ingredients other than inert diluents, such as lubricating agents (e.g., magnesium stearate) or solubilizing agents (e.g., cyclodextrin), as is conventional in the art. In the case of capsules, tablets, powders, granules, gel covers and pills, the formulations may also contain buffering agents. Tablets and pills may additionally be prepared with enteric fat.
[136] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert excipients commonly used in the art, such as water. Such compositions may also include wetting agents, emulsifying and suspending agents, and reinforcing agents such as sweeteners, flavoring agents and fragrances.
[137] Appropriate dispersing or suspending agents and suspending agents may be used to make injectable preparations, such as sterile injectable aqueous or oily suspensions, according to methods known in the art. The sterile injectable preparation may also be a sterile injectable solution or suspension in an excipient or solvent that is non-toxic and suitable for parenteral administration, such as a solution in 1,3-butanediol. Among the acceptable excipients and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fat oils are conventionally employed as a solvent or suspending medium. For this purpose any emollient fat oil may be used including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables.
[138] Pharmaceutically acceptable carriers include all of the foregoing, and the like.
[139] In the combination therapy, two or more therapeutic agents useful in the present invention may be sequentially administered in separate formulations, or may be co-administered with one agent or in separate formulations.
[140] Administration can be by oral route or by intravenous, intramuscular, or subcutaneous injection. The formulation may be in the form of a mass, or in the form of an aqueous or non-aqueous isotonic sterile injectable solution or suspension. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically acceptable carriers or excipients, or a binder such as gelatin or hydroxypropylmethylcellulose, in combination with one or more lubricants, preservatives, surface active agents or dispersants.
[141] For oral administration, the pharmaceutical compositions may be in the form of, for example, tablets, capsules, suspensions or liquids. Capsules, tablets, etc. may be prepared by conventional methods in the art. The pharmaceutical compositions are preferably prepared in unit dosage form containing a specified amount of the active ingredient or ingredients. Examples of unit dosage forms are tablets or capsules. They may be advantageous to contain one or more therapeutic compounds in the amounts indicated above. For example, in the case of an IBAT inhibitor, the dosage range may be from about 0.01 mg / day to about 500 mg / day, or may be any other dosage depending on this particular inhibitor as is known in the art. In the case of bile acid sequestrants, the dosage range may be from about 1,000 mg / day to about 30,000 mg / day, or may be any other dosage depending on this particular bile acid sequestrant as is known in the art.
[142] The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose, or water may be used as a suitable carrier. A suitable daily dose of each active therapeutic compound is an amount that achieves the same serum concentration as produced by oral administration as described above.
[143] The therapeutic compounds may also be administered by any combination of oral / oral, oral / parenteral, or parenteral / parenteral routes.
[144] The pharmaceutical compositions for use in the methods of treatment of the present invention may be administered orally or by intravenous administration. Oral administration of the combination therapy is preferred. Administration of the medicament for oral administration may consist of a once-a-day administration, a once-in-a-day administration, or a regimen requiring multiple administrations at intervals throughout the day. Therapeutic compounds that make up the combination therapy may be administered simultaneously in a combined dosage form or in separate dosage forms for substantial concurrent oral administration. Therapeutic compounds that make up the combination therapy may also be administered sequentially, with one therapeutic compound being administered by a regimen requiring a two-stage intake. Thus, the regimen may require sequential administration of the therapeutic compound while taking the separated active agent at intervals. The time period between multiple ingestion steps may be from minutes to hours and is dependent on the nature of each therapeutic compound, such as the performance, solubility, bioavailability, plasma half-life, and kinetic profile of the therapeutic compound, And the condition. The cyclic change in the target molecule concentration may also determine the appropriate dosage interval. The therapeutic compounds of the combination therapy may be associated with a regimen requiring simultaneous administration, sequential simultaneous or sequential administration, one therapeutic compound administered orally and the other therapeutic compound administered intravenously. Therapeutic Compounds of the Combination Therapy Whether administered by the oral or intravenous route, separately or together, each such therapeutic compound will be contained within a suitable pharmaceutical formulation of a pharmaceutically acceptable excipient, diluent or other agent component. Examples of suitable pharmaceutically acceptable preparations containing therapeutic compounds for oral administration are given above.
[145] Therapeutic regimen
[146] The use of the compounds and / or compositions of the present invention to prevent, ameliorate, or ameliorate disease states having hyperlipidemia as an element of the disease, such as atherosclerosis, or to prevent high plasma or blood cholesterol concentrations Dosage regimens for treatment are selected according to various factors. These include, but are not limited to, the type of patient, age, weight, sex, diet and medical condition, severity of the disease, route of administration, pharmacological considerations such as activity, efficacy, pharmacokinetics and toxicology profile of the specific compound employed, , And whether the compound is administered as part of a combination of agents. Thus, the dosage regimens actually employed may vary widely and may deviate from the preferred dosage regimens described above.
[147] And the initial treatment of a patient suffering from a lipidemia condition may begin with the administration described above. Treatment should generally be continued as needed over a period of weeks to months or years until the status of the hyperlipidemic disease is modulated or eliminated. Patients undergoing treatment with the compounds or compositions disclosed herein may be routinely monitored by measuring serum LDL and total cholesterol concentrations by any method known in the art in order to determine the efficiency of the combination therapy. Sequential analysis of such data enables modification of therapeutic regimens during treatment, allowing an appropriate effective amount of each type of therapeutic compound to be administered at any time, and also allowing the duration of treatment to be determined. In this way, the therapeutic regimens / drug administration schedules are rationally modified throughout the course of the treatment so that a minimum amount of therapeutic compounds which together represent a satisfactory effect can be administered and administered only during the time needed to successfully treat the hyperlipidemic condition .
[148] A possible advantage of the combination therapies disclosed herein is the ability to reduce the dosage of individual therapeutic compounds or all therapeutic compounds effective to treat hyperlipidemic conditions such as atherosclerosis and hypercholesterolemia. Such a dose reduction would provide advantages, including reduced side effects of the individual therapeutic compounds, when compared to a single treatment.
[149] One of several embodiments of the present invention includes combination therapy comprising the use of a first amount of an IBAT inhibitor and a second amount of another cardiovascular therapeutic agent useful for the prevention or treatment of hyperlipidemia, atherosclerosis or hypercholesterolemia, Wherein said first and second amounts together constitute an effective amount of an anti-hyperglycemic condition, an anti-atherosclerosis condition condition or an anti-hypercholesterolemia condition of said compounds. For example, one of many embodiments of the present invention is a combination therapy comprising a therapeutic dose of an IBAT inhibitor and a CETP inhibitor. A preferred embodiment of the present invention is a combination therapy comprising a therapeutic dose of a benzothiophene IBAT inhibitor and a CETP inhibitor.
[150] Embodiments of the invention may include combination therapies using two or more therapeutic compounds described and recited herein. Combination therapies may contain more than one therapeutic compound from another class of chemistry, for example, an IBAT inhibitor may be therapeutically associated with a CETP inhibitor. Therapeutic combinations can include two or more therapeutic compounds. For example, the therapy may contain an IBAT inhibitor, a CETP inhibitor and an HMG CoA reductase inhibitor. Alternatively, two or more therapeutic compounds from the same class of chemistry may constitute a therapy, for example, a combination therapy may contain two or more IBAT inhibitors or two or more CETP inhibitors.
[151] Another embodiment of the present invention includes the use of any of the combinations of cardiac disease therapies described herein to prevent or treat hypercholesterolemia, atherosclerosis or hyperlipidemia.
[152] The following non-limiting examples illustrate various aspects of the present invention.
[153] Table 3 shows examples of multiple combinations of the present invention wherein the combinations comprise a first amount of an IBAT inhibitor and a second amount of a CETP inhibitor, wherein the first amount and the second amount together form an anti-hyperlipidemic effective amount , An effective amount of an anti-atherosclerotic condition or an anti-hypercholesterolemic condition.
[154] [ Table 3 ]
[155]
[156]
[157]
[158]
[159]
[160]
[161]
[162]
[163]
[164]
[165]
[166]
[167]
[168]
[169]
[170]
[171]
[172]
[173] Biological analysis
[174] The usefulness of the combination of the present invention can be shown by the following analysis. These assays are performed in animal models and in vitro using recognized procedures to demonstrate the utility of the present invention.
[175] Lt; RTI ID = 0.0 > IBAT-mediated & ¹⁴ C] - In vitro analysis of compounds that inhibit the absorption of taurocholate (TC)
[176] Human hamster kidney cells (BHK) (H14 cells) transfected with human IBAT cDNA were seeded and expanded to 60,000 cells / well in a 96-well top-count tissue culture plate for analysis within 24 hours after seeding , 30,000 cells / well for analysis were developed within 48 hours and 10,000 cells / well for analysis were developed within 72 hours.
[177] On the day of analysis, the cell monolayer was mildly lysed with 100 μl of assay buffer (Dulbecco's modified Eagle's medium containing bovine serum albumin- (FAF) BSA in the absence of 4.5 g / L glucose + 0.2% (w / v) fatty acid Washed once. Twice 50㎕ concentrate of test compound in the assay buffer to each well 6μM ^[14 C] in the assay buffer, - a tau cholate 50㎕ - was added with (final concentration 3μM ^[14 C] to the cholate being Tau). Cell culture plates were incubated at 37 ° C for 2 hours and then each well was washed twice with 100 μl of 4 ° Dulbecco's phosphate buffered saline (PBS) containing 0.2% (w / v) (FAF) BSA Respectively. Followed by gentle washing once with 100 [mu] l of 4 [deg.] PBS without (FAF) BSA. The liquid scintillation count fluid was added to each, the plate was sealed with heat, stirred at room temperature for 30 minutes, and then the dose of each well was measured on a packed card-top-counter instrument.
[178] [ ¹⁴ C] - In vitro analysis of compounds inhibiting alanine uptake
[179] The alanine uptake assay was performed in the same manner as the taurocholate assay except that the labeled alanine was used instead of the labeled taurocholate.
[180] Measurement of rat bile bile acid concentration (FBA)
[181] All sides from individual inhabited rats were collected for 24 or 48 hours, dried under a nitrogen stream, milled, mixed and weighed. Approximately 0.1 gram was measured and extracted into an organic solvent (butanol / water). After separation and drying, the amount of bile acid present was determined enzymatically using the reaction of 3α-hydroxysteroid steroid dehydrogenase and bile acid to dissolve the residue in methanol and reduce NAD (Mashige, F. et al. Clin. Chem., 27 , 1352 (1981), incorporated herein by reference).
[182] Rat feeding analysis
[183] Male Wistar rats (275-300 g) were administered an IBAT inhibitor using an oral feeding procedure. Drugs or excipients (0.2% TWEEN 80 in water) were administered at various doses in a final volume of 2 ml / kg body weight once per day (9: 00-10: 00 a.m.) for 4 days. (TWEEN 80 is a 20 mole polyethylene oxide sorbitan monooleate surfactant manufactured by ICI Specialty Chemicals (Wilmington, Delaware, USA). Total sided samples were collected during the last 48 hours of the treatment period, Enzyme analysis was used to analyze the amount of bile acid. Compound efficacy was determined by comparing the increase in bile bile acid (FBA) concentration in the treated rats to the mean FBA concentration of the rats in the vehicle group.
[184] In rabbit brush border canal (BBMV) ³ H] taurocholate absorption
[185] A rabbit venom brush bordering membrane was prepared from the freezing ileum mucosa by the calcium precipitation method ( Biochimica Biophysica Acta, 554, 259 (1979), incorporated herein by reference). The method for measuring taurocholate is as described by Cramer et al. ( Biochimica Biophysica Acta, 1111 , 93 (1992), hereby incorporated by reference) except that the assay volume is 200 μl instead of 100 μl. To summarize, 190 μl of a solution containing 2 μM [ ³ H] -tauracholate (0.75 μCi), 20 mM Tris, 100 mM NaCl and 100 mM mannitol pH 7.4 at room temperature was added to 10 μl of brush border vesicle (60-120 μg protein) And incubated for 5 seconds. The incubation was started by adding BBMV with vortexing, adding 5 ml of ice-cold buffer (20 mM Hepes-tris, 150 mM KCl) and then immediately filtering through a nylon filter (0.2 μm pore) and washing once more with 5 ml stop buffer The reaction is stopped.
[186] Measurement of liver cholesterol concentration (HEPATIC CHOL)
[187] Liver tissue was weighed and homogenized in chloroform: methanol (2: 1). After homogenization and centrifugation, the supernatant was separated and dried under nitrogen. The residue is dissolved in isopropanol and the amount of cholesterol is measured using a combination of cholesterol oxidase and peroxidase as disclosed in Clin. Chem., 20, 470 (1974) (herein incorporated by reference) Were measured enzymatically.
[188] Measurement of liver HMG CoA-reductase activity (HMG-COA)
[189] Liver microsomes were prepared by homogenizing liver samples in phosphate / sucrose buffer and then centrifuging. The final precipitated material was resuspended in buffer and a fraction of the fraction was analyzed for HMG CoA reductase activity by incubation at 37 < 0 > C for 60 min in the presence of ¹⁴ C-HMG-CoA (Dupont-NEN). The reaction was stopped by adding 6N HCl and centrifuging. The supernatant was fractionated by thin layer chromatography, and the portion corresponding to the enzyme product was scraped from the plate and extracted, and the radioactivity was determined by a scintillation counter (see, for example, Akklund, J. and Borghem, 1990) J. Lipid Res. 31 , 2159).
[190] Measurement of liver cholesterol 7-alpha-hydroxylase activity (7a-OHase)
[191] Liver samples were homogenized in phosphate / sucrose buffer and separated by centrifugation to prepare liver microsomes. The final precipitated material was resuspended in buffer and a portion of the fraction was analyzed for cholesterol 7-alpha -hydroxylase activity by incubation at 37 < 0 > C for 5 min in the presence of NADPH. After extraction into petroleum ether, the organic solvent was evaporated and the residue was dissolved in acetonitrile / methanol. An aliquot of the extract was injected onto a C ₁₈ reversed phase HPLC column and the eluted material was quantified by UV detection at 240 nm to isolate the enzyme product (see Holton, J. D. et al. (1994) J. Clin. Invest . 93 , 2084).
[192] Measurement of serum cholesterol (SER.CHOL, HDL-CHOL, TGI and VLDL + LDL)
[193] A kit available from Wako Fine Chemical (Richmond, Va.); Total cholesterol (SER.CHOL) was measured enzymatically using cholesterol C11, catalog No. 276-64909. HDL-cholesterol (HDL-CHOL) was analyzed using the same kit after precipitating VLDL and LDL with Sigma Chemical Co.'s HDL cholesterol reagent, catalog No. 362-3 (dextran sulfate method). Total serum triglyceride (blank) (TGI) was enzymatically analyzed with Sigma Chemical Company's GPO-Trinder, Catalog No. 377-B. VLDL and LDL (VLDL + LDL) cholesterol concentrations are calculated as the difference between total cholesterol and HDL cholesterol.
[194] Measurement of fecal bile acid (FBA) concentration in hamsters
[195] The total effluent of each housed hamster was collected for 24 or 48 hours, dried under nitrogen gas flow, crushed and weighed. Weighed to approximately 0.1 gram, and extracted with an organic solvent (butanol / water). After separation and drying, the residue is dissolved in methanol and the amount of bile acid present is enzymatically determined, using a 3 -Hydroxysteroid steroid dehydrogenase reaction with bile acid to reduce NAD. (Mashige, F. et al. Clin. Chem., 27 , 1352 (1981), incorporated herein by reference).
[196] Dog model for evaluation of lipid-lowering drugs
[197] A 6-12 kg male beagle dog, purchased from a seller such as Marshall Farm, was fed for 2 hours a day and allowed the water to drink at will. The dogs can be arbitrarily divided into a group consisting of 6 to 12 dogs each. The dose groups were as follows: vehicle, i.g .; 1 mg / kg, i.g .; 2 mg / kg, i. G .; 4 mg / kg, i. 2 mg / kg, p.o. (powder in capsule). Intragastric administration of a therapeutic agent dissolved in an aqueous solution (e.g., 0.2% Tween 80 solution [olyoxyethylene mono-oleate, Sigma Chemical Co., St. Louis, Mo., USA] may be performed using a gavage tube. Blood samples can be taken from the head vein in the morning before feeding to assess serum cholesterol (total and HDL) and triglyceride, before initiation of administration. The animals were administered to the animals in the morning prior to feeding for consecutive days. Animals were fed for 2 hours before any remaining food was removed. At the conclusion of this study, two days of fecal samples can be collected and analyzed for bile acid or lipid content. Also, at the end of the treatment period, a blood sample was taken to compare with pre-study serum lipid levels. Statistical significance can be determined using a standard Student T-test (p <.05).
[198] Dog serum lipid measurement
[199] Blood was collected from dog head veins that were not fed with a serum separator tube (Vacutainer SST, Becton Dickinson and Co., Franklin Lakes, New Jersey, USA). Blood was centrifuged at 2000 rpm for 20 minutes and serum was taken.
[200] Total cholesterol can be measured using a cholesterol oxidase reaction that produces colorless, quantitatively measured hydrogen peroxide in a 96 well format using the Wako Enzyme Assay Kit (cholesterol CII) (Wako Chemicals, Richmond, VA). A standard curve of 0.5 to 10 ug cholesterol is obtained in the first two columns of the plate. Serum samples (20-40 [mu] l depending on the predicted lipid concentration) or known serum control samples were added to separate double wells. Water was added to each well to a volume of 100 [mu] l. 100 [mu] l aliquots of the color reagent are added to each well and the plate will be measured at 500 nm after 15 minutes at 37 [deg.] C.
[201] HDL cholesterol can be analyzed using Sigma Kit No. 352-3 (Sigma Chemical Co., St. Louis, Mo.), which selectively precipitates LDL and VLDL using dextran sulfate and Mg ions. After adding 150 각 of each serum sample to each centrifuge tube, 15 HD of HDL cholesterol reagent (Sigma 352-3) was added. Samples were mixed and centrifuged at 5000 rpm for 5 minutes. Then, the supernatant solution (50.) Was mixed with 200 쨉 l of brine and analyzed using the same method as in the case of total cholesterol measurement.
[202] Triglyceride was measured using Sigma Kit No. 337 in a 96 well plate format. This method measures glycerol, and then measures the release of glycerol by the reaction of lipoprotein lipase and triglyceride. A glycerol standard solution (Sigma 339-11) ranging from 1 to 24 μg will be used to generate a standard curve. Serum samples (20-40 [mu] l depending on the expected lipid concentration) were added to the double wells. Water was added to each well to a volume of 100 占 퐇, and 100 占 퐇 of the coloring reagent was added to each well. After mixing and incubation for 15 minutes, the plate was measured at 540 nm and the triglyceride value was calculated from the standard curve. Cloning plates were also developed using blank enzyme reagents to correct for endogenous glycerol in serum samples.
[203] Measuring Enhanced Biliary Acid
[204] Fecal samples can be collected to determine fecal bile acid (FBA) concentration in each animal. Fecal collection can be done for two consecutive 24-hour periods, from 9 am to 10 am daily, for the last 48 hours of the study, prior to dosing and feeding. Separate two-day collections of each animal were weighed, pooled and homogenized with distilled water in a Cuisinart to make a homogeneous slurry. Approximately 1.4 g of the homogenate was extracted in a tertiary butanol / distilled water (2: 0.6) at a final concentration of 50% for 45 minutes in a 37 ° C water bath and centrifuged at 2000 x g for 13 minutes. The concentration of bile acid (mmole / day) can be determined using a 96-well enzyme assay system (1, 2). A 20 [mu] l aliquot of the lateral extract was added to two sets of triple wells each on a 96-well assay plate. The standardized sodium taurocholate solution and the standardized fecal extract solution (made from previously collected samples and characterized for bile acid concentration) will also be analyzed for analysis quality control. 20 [mu] l of sequentially diluted sodium taurocholate to produce a standard curve is similarly added to both sets of triplet wells. 230 [mu] l of a reaction mixture containing 1 M hydrazine hydrate, 0.1 M pyrophosphate and 0.46 mg / ml NAD was added to each well. A 50 [mu] l aliquot of 3 [alpha] -hydroxysteroid dehydrogenase (HSD; 0.8 units / ml) or assay buffer (0.1M sodium pyrophosphate) was then added to one of the two sets of triple wells. All reagents are available from Sigma Chemical Co. of St. Louis, Missouri, USA. After 60 minutes of incubation at room temperature, the optical density at 340 nm will be measured and the average of each set of triplicate samples will be calculated. The optical density difference ± HSD enzyme was used to determine the bile acid concentration (mM) of each sample based on the sodium taurocholate standard curve. The concentration of bile acid in the extract, the weight (gram) of the fecal homogenate and the body weight of the animal were used to calculate the corresponding FBA concentration in mmole / kg / day in each animal. The mean FBA concentration (mmole / kg / day) of the vehicle group is subtracted from the FBA concentration of each treatment group to determine the increase (delta value) of the FBA concentration as a result of the treatment.
[205] Analysis of plasma lipids in rabbits
[206] Plasma lipids were obtained from JRSchuh et al. J. Clin. Invest ., 91, 1453-1458 (1993), incorporated herein by reference). A group of male New Zealand white rabbits were fed standard (100 g / day) supplemented with 0.3% cholesterol and 2% corn oil (Zeigler Bothers, Inc., Gardners, PA, USA). I let the water drink at will. After 1 month and 3 months of treatment, control groups and groups of treated animals were killed. Tissue was removed for the identification of atherosclerotic signs. Blood samples were taken to determine plasma lipid concentrations.
[207] Plasma lipid
[208] Plasma for lipid analysis was obtained by releasing blood from the ear vein into an EDTA-containing tube (Vacutainer; Becton Dickenson & Co., Rutherford, New Jersey, USA) and isolating the cells by centrifugation. Total cholesterol was determined enzymatically using cholesterol oxidase reaction. (CA Allain et al., Clin. Chem. , 20, 470-475 (1974), incorporated herein by reference). HDL cholesterol was also enzymatically measured after selective precipitation of LDL and VLDL by magnesium and dextran sulfate. (GR Warnick et al., Clin. Chem. , 28, 1379-1388 (1982), incorporated herein by reference). Plasma triglyceride levels will be determined by measuring the amount of glycerol released by the lipoprotein lipase via enzyme-linked assays. (G. Bucolo et al., Clin. Chem., 19, 476-482 (1973), incorporated herein by reference).
[209] Atherosclerosis
[210] Animals were killed by pentobarbital injection. The thoracic aorta was rushed out, immersed in 10% neutral buffered formalin, and stained with oil red O (0.3%). After a single longitudinal incision along the wall opposite the artery pore, the vessel was pinned open for evaluation of the plaque area. The percent plaque range was determined using a threshold using a true color image analyzer (Videometric 150; American Innovision, Inc., San Diego, Calif.) Connected to a color camera (Toshiba 3CCD) mounted on a dissecting microscope. By analysis, it was determined from the total area and the value of the stained area. Tissue cholesterol is enzymatically degraded as described after extraction with a chloroform / methanol mixture (2: 1) according to the method of Folch et al. (J. Biol. Chem. 226, 497-509 (1957) &Lt; / RTI &gt;
[211] In vitro vascular response
[212] After injection of sodium pentobarbital, the abdominal artery was rapidly dissected and placed in an oxygenated Krebs-bicarbonate buffer. After removal of the surrounding vascular tissue, the 3-mm ring section was cut, placed in a 37 ° C muscle bath containing Krebs-bicarbonate solution, and two stainless steel tubes, one attached to a force transducer (Grass Instrument Co., Quincy, Mass., USA) Hanging between the steel wires. A change in force will be recorded on the chart recorder in response to angiotensin II added to the aquarium.
[213] CETP activity assay in human plasma (Tritiated cholesteryl ester)
[214] Blood was obtained from a healthy volunteer. Blood was collected in tubes containing EDTA (EDTA plasma pool). The EDTA human plasma pool previously stored at 20 ° C was dissolved at room temperature and centrifuged for 5 minutes to remove any particulate components. Tritiated HDL is described by Morton and Zilversmit [ J. Biol. (25 μg / ml cholesterol) was added to the plasma with the cholesteryl ester moiety as a radiolabelled ([ ³ H] CE-HDL) as described in J. Chem ., 256 , 11992-95 . The inhibitor compound was added to the plasma as follows: ^[3 H] was added to the CE-HDL (396㎕) micro tubes ^{(Titertube R, Bio-Rad laboratories} , Hercules, CA) with an equal volume of plasma containing pipette. The compound dissolved as a 20-50 mM stock solution in DMSO usually is sequentially diluted with DMSO (or alternatively an alternative solvent such as dimethylformamide or ethanol in some cases). Subsequently, 4 μl each of sequential dilutions of the inhibitor compound or DMSO alone was added to each plasma tube. The tubes were immediately mixed. The tritiated aliquots (100 [mu] l) from each plasma tube were transferred to the wells of 96-well polystyrene microtiter round plates (Corning, Corning, NY). The plate was sealed with a plastic film and incubated at 37 [deg.] C for 4 hours. Dilutions of inhibitor compounds were included in the test wells. Control wells contained plasma with DMSO alone. Blankwell contained plasma with a single DMSO incubated at 4 [deg.] C for 4 hours in microtube and added to microtiter wells at the end of the incubation period. VLDL and LDL were precipitated by adding 10 [mu] l of precipitant (1% (w / v) Dextralip50 / 0.5 M magnesium chloride, pH 7.4) to all wells. The wells were mixed on a flat plate mixer and then incubated for 10 minutes at ambient temperature. Then, the plate was centrifuged at 1000 占 폚 for 30 minutes at 10 占 폚. The supernatant (50 μl) from each well was then transferred to a Picoplate 96 plate well (Packard ^™ , Meriden, CT) containing 250: 1 Microscint ^™ -40 (Packard ^™ , Meriden, CT). The plates were sealed with heat and mixed for 30 minutes according to the manufacturer's instructions (TopSeal ^TM -p, packard, Meriden, CT). The radioactivity will be measured on a fine plate scintillation counter (TopCount, Packard, Meriden, CT). IC ₅₀ values will be determined as concentrations of inhibitory compounds that inhibit [ ³ H] CE transfer by up to 50% to VLDL and LDL precipitated from supernatant [ ³ H] CE-HDL as compared to transfer from control wells . The maximum percentage transfer (in the control well) will be determined by the following equation.
[215] % Transfer = ( ^dpm blank- ^dpm control) x 100 / ^dpm blank
[216] The percentage of control transfer measured in the well containing the inhibitor compound will be determined by the following equation.
[217] % Control group = ( ^dpm blank- ^dpm test) 占 100 / ^dpm blank- ^dpm control group
[218] IC ₅₀ values will be calculated from the graph of% control versus inhibitor concentration.
[219] In vitro CETP activity
[220] The activity of compounds that inhibit CETP activity was assessed using in vitro assays to determine the rate of delivery of radiolabeled cholesteryl esters ([ ³ H] CE) from HDL-providing particles to LDL-receiving particles. A detailed description of the assay can be found in Glenn et al. (Glenn and Melton, "Quantification of Cholesteryl Ester Transfer Protein (CETP): A) CETP Activity and B) Immunochemical Assay of CETP Protein, Meth. Enzymol., 263, 339-351 (1996). CETP can be obtained from serum-free restriction medium of CHO cells transfected with cDNA for CETP [Wang, S. et al. J. Biol. Chem. 267, 17487-17490 (1992)). To determine the CETP activity, the [ ³ H] CE-labeled HDL, LDL, CETP and analytical buffer (50 mM Tris (hydroxymethyl) aminomethane, pH 7.4; 150 mM NaCl; 2 mM ethylenediaminetetraacetic acid; Serum albumin) was incubated at 37 [deg.] C for 2 hours in a volume of 200 [mu] l in a 96 well plate. LDL was fractionally precipitated by adding 1% (w / v) dextran sulfate / 0.5 M magnesium chloride, mixing by vortexing, and incubating at room temperature for 10 minutes. The solution (200 μl) was transferred to a filter plate (Millipore). After filtration, the radioactivity present in the precipitated LDL was measured with a liquid scintillation counter. Non-specific delivery or precipitation was corrected by including a sample that did not contain CETP. The [ ³ H] CE transfer rate using this assay is expressed in terms of time and CETP concentration up to 25-30% delivered [ ³ H] CE.
[221] The potential ability of the test compound can be determined by performing the assay in the presence of various concentrations of the test compound and measuring the concentration necessary to inhibit [ ³ H] CE transfer from HDL to LDL. This value is defined as IC ₅₀ . The IC ₅₀ values determined in this assay are accurate when the IC ₅₀ is greater than 10 nM. If compounds have greater inhibitory potency, accurate determination of IC ₅₀ can be determined using longer incubation times (up to 18 hours) and lower CETP concentrations (< 50 nM).
[222] Inhibition of CETP activity in vivo
[223] Inhibition of CETP activity by the test compound can be assessed by administering the compound to animals in an intravenous or oral gavage and determining the amount of tritiated-labeled cholesteryl ester [ ³ H] CE transfer from HDL to VLDL and LDL particles This can be determined by comparison with the amount of delivery observed in the control animals.
[224] The male Golden Syrian hamsters for more than 2 weeks were continuously examined with food containing 0.24% cholesterol. For animals dosed intravenously, they were anesthetized with pentobarbital immediately before the test. Anesthesia was maintained during the test. In-dwelling catheters were inserted into the jugular vein and carotid artery. At the beginning of the experiment, all animals will be given 0.2 ml of [ ³ H] CE-HDL solution in the jugular vein. [ ³ H] CE-HDL is a human HDL preparation containing tritium-labeled cholesteryl esters and is described by Glenn et al . [ Meth. Enzymol ., 263 , 339-351 (1996). The test compounds were dissolved as an 80 mM stock solution in vehicle (2% ethanol: 98% PEG 400, Sigma Chemical Company, St. Louis, Missouri, USA) and administered by bolus injection or continuous infusion. Two minutes after administration of [ ³ H] CE-HDL dose, animals were given 0.1 ml test solution into the jugular vein. Control animals received 0.1 ml of vehicle-free vehicle-free vehicle without test compound. After 5 minutes, an initial blood sample (0.5 ml) was taken from the carotid artery and collected in standard microtainer tubes containing ethylenediaminetetraacetic acid. The catheter was rinsed with saline (0.5 ml) to replace the blood volume. Subsequent blood samples were taken at 2 and 4 hours in the same manner. Blood samples were mixed well and stored on ice until the experiment was terminated. Blood samples were centrifuged at 4 ° C to obtain plasma. Plasma (50 μl) was treated with 5 μl of a precipitant (dextran sulfate, 10 g / l; 0.5 M magnesium chloride) to remove VLDL / LDL. After centrifugation, the resulting supernatant (25)) containing HDL was analyzed for radioactivity using a liquid scintillation counter.
[225] The [ ³ H] CE percentage (% transfer) from HDL to LDL and VLDL is calculated based on total radioactivity in the plasma sample before precipitation. Typically, the amount of delivery from HDL to LDL and VLDL in control animals is 20% to 35% after 4 hours.
[226] Alternatively, untreated conscious animals were administered oral gavage as test compounds as a suspension of 0.1% methylcellulose in water. At the measured times of each compound with plasma levels of the oral test substance reaching a peak (C _max ), the animals were anesthetized with pentobarbital and then 0.2 ml of the [ ³ H] CE-HDL containing solution was injected into the jugular vein . Control animals were administered 0.25 ml of the vehicle-free vehicle solution with oral gavage. After 4 hours, the animals were sacrificed, blood samples were collected and the [ ³ H] CE percentage (% transfer) transferred from LDL to LDL and VLDL was analyzed as above.
[227] Alternatively, inhibition of CETP activity by a test compound can be measured by administering the test compound to a selected mouse expressing human CETP (hCETP) by transgene manipulation. The test compound was administered intravenously or oral gavage and the amount of tritiated-labeled cholesteryl ester ([ ³ H] CE) delivered from HDL to VLDL and LDL particles was measured and compared to the amount of delivery observed in the control animals . C57Bl / 6 mouse, which is a homozygous hCETP gene, was fed with high fat diet for more than 2 weeks, for example, by TD 88051 as disclosed by Nishina et al. [ J Lipid Res ., 31, 859-869 (1990) Respectively. Mice can be administered orally with a test compound in a suspension of 0.1% methylcellulose in water or intravenously injected with a test compound in 10% ethanol and 90% polyethylene glycol. Control animals received an injectable solution of the test compound in the oral gavage or intracoronary bolus injection. At the beginning of the experiment, 0.05 ml of [ ³ H] CE-HDL containing solution was administered into the tail vein to all animals. [ ³ H] CE-HDL is a preparation of human HDL containing tritium-labeled cholesteryl esters and is described by Glenn et al . [ Meth. Enzymol ., 263 , 339-351 (1996). After 30 minutes, blood was drawn from the animal and blood was collected in standard microtainer tubes containing ethylenediaminetetraacetic acid. Blood samples were mixed well and stored on ice until the experiment was terminated. Blood samples were centrifuged at 4 ° C to obtain plasma. Plasma was isolated and analyzed by gel filtration chromatography to determine the relative ratio of [ ³ H] CE in the VLDL, LDL and HDL regions.
[228] The [ ³ H] CE percentage (% transfer) from HDL to LDL and VLDL is calculated based on total radioactivity in the plasma sample before precipitation. Typically, the amount of delivery from HDL to LDL and VLDL in control animals is 20% to 35% after 4 hours.
[229] Cholesterol absorption analysis in intestines
[230] Various compounds have been shown to inhibit cholesterol absorption from the intestinal tract. These compounds reduce serum cholesterol levels by reducing intestinal absorption of cholesterol from an exogenous source (cholesterol by food ingestion) and endogenous cholesterol (secreted by the gall bladder by the gall bladder).
[231] The use of the double-isotope plasma ratio method to measure intestinal cholesterol absorption in hamsters has been improved and evaluated as described by Turley et al. (J. Lipid Res. 35, 329-339 (1994) , Incorporated herein by reference).
[232] A male hamster of 80-100g was allowed to eat food and water at will in a room with 12 hours of light alternating. After entering the light period, at 4 hours, each hamster was first administered intravenously with 2.5 μCi of [1,2- ³ H] cholesterol suspended in Intralipid (20%), followed by mid-chain triglyceride ) Of [4- ¹⁴ C] cholesterol in the oil was orally administered. Intravenous administration was made by injecting 0.4 ml of Intralipid mixture into the distal femoral vein. Oral administration was made by introducing 0.6 ml of the MCT oil mixture into the stomach through a polyethylene tube. After 72 hours the blood of the hamster was bled and the amount of ³ H and ¹⁴ C in the plasma and the original amount of label administered was determined by liquid scintillation spectrometry. Cholesterol absorption will be calculated according to the formula:
[233] Percent absorbed cholesterol =
[234] % Of oral dose per ml of 72 hour plasma sample
[235] % Of intravenous dose per ml of 72 hour plasma sample &lt; RTI ID = 0.0 &gt;
[236] The embodiments herein can be carried out by replacing with the therapeutic compounds or inactive components described generically or specifically instead of those used in the above embodiments.
[237] Although the present invention has been described herein, it is evident that the same can be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such variations and modifications apparent to those skilled in the art are intended to be included within the scope of the following claims.

权利要求:
Claims (9)
[1" claim-type="Currently amended] A first amount of a venous bile acid transport inhibiting compound and a second amount of a cholesteryl ester transfer protein inhibiting compound, wherein said first and second amounts together are an amount effective for the anti-hyperlipidemic state of the compound, an anti-atherosclerotic A therapeutically effective amount in an arteriosclerotic condition or an amount effective in an anti-hypercholesterolemic condition.
[2" claim-type="Currently amended] The therapeutic combination according to claim 1, wherein the ileum bile acid transport inhibiting compound is a compound having the structure of formula (B-2) or an enantiomer thereof or a racemate thereof.
[Formula B-2]
[3" claim-type="Currently amended] The therapeutic combination according to claim 1, wherein the ileum bile acid transport inhibiting compound is a compound having the structure of formula (B-12) or an enantiomer thereof or a racemate thereof.
[Formula B-12]
[4" claim-type="Currently amended] The method of claim 1, wherein the ileum bile acid transport inhibiting compound is a compound having the structure of formula B-29 or an enantiomer or racemate thereof, wherein PEG is a polyethylene glycol polymer chain of about 3000 to about 4000 molecular weight Therapeutic combination.
[Chemical formula B-29]
[5" claim-type="Currently amended] The therapeutic combination according to claim 1, wherein the ileum bile acid transport inhibiting compound is a compound having the structure of formula (B-7) or an enantiomer thereof or a racemate thereof.
[Formula B-7]
[6" claim-type="Currently amended] 2. The therapeutic combination of claim 1, wherein the combination comprises a composition comprising an ileal bile acid transport inhibiting compound and a cholesteryl ester transport protein inhibiting compound.
[7" claim-type="Currently amended] Comprising administering to a patient in need thereof a combination of a first amount of a venous bile acid transport inhibiting compound and a second amount of a cholesteryl ester transport protein inhibiting compound And wherein said first and second amounts together comprise an amount effective for the anti- and lipidemic conditions of the compound.
[8" claim-type="Currently amended] Comprising administering a combination in the form of a unit dosage form to a patient suffering from atherosclerosis, the combination comprising a first amount of a venous bile acid transport inhibiting compound and a second amount of a cholesteryl ester transport protein inhibiting compound And wherein said first and second amounts together comprise an amount effective for the anti-atherosclerotic condition of the compound.
[9" claim-type="Currently amended] Comprising administering to a patient in a hypercholesterolemic condition a combination in the form of a unit dosage form, wherein the combination comprises a first amount of a venous bile acid transport inhibiting compound and a second amount of a cholesteryl ester transport protein inhibiting compound And wherein said first and second amounts together comprise an amount effective for the anti-hypercholesterolemic state of the compound.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6443950B2|2018-12-26|Bile acid recirculation inhibitors for the treatment of childhood cholestatic liver disease

---

Goldstein et al.1975|Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339.

---

Tobert1987|New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.

---

Abelson et al.1993|Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy

---

Ohtake et al.2004|In vitro and in vivo tissue selectivity profile of solifenacin succinate | for urinary bladder over salivary gland in rats

---

Osamah et al.1997|Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets

---

Mauro1993|Clinical pharmacokinetics and practical applications of simvastatin

---

US7416744B2|2008-08-26|Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use

---

DE69636783T2|2007-10-18|Method and pharmaceutical composition for regulating lipid concentration

---

KR100882335B1|2009-02-11|Compounds and methods for the inhibition of the expression of vcam-1

---

US6139873A|2000-10-31|Combined pharmaceutical estrogen-androgen-progestin

---

US5962464A|1999-10-05|Methods and compositions for treating allergic asthma using descarboethoxyloratadine

---

Salen et al.1992|Sitosterolemia.

---

US5731319A|1998-03-24|Methods for treating disorders using descarboethoxyloratadine

---

EP0768895B1|2004-09-22|Camptothecin drug combinations and medicaments with reduced side effects

---

US5631267A|1997-05-20|Method for the treatment of eosinophil-associated diseases by administration of topical anesthetics

---

EP1513519B1|2009-02-18|The use of substituted cyanopyrrolidinesfor treating hyperlipidemia

---

US5731326A|1998-03-24|PDGF antagonists II

---

DE60127410T2|2007-12-13|Combination therapy with epoxy-steroidal aldosterone antagonists and calcium channel blocks for the treatment of congestive heart failure

---

US5393772A|1995-02-28|Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation

---

ES2264679T3|2007-01-16|Procedure to treat obesity using a neurotensin receiver link.

---

Bard et al.1992|A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

---

US20020055529A1|2002-05-09|Method for treating alzheimer&#39;s disease

---

JP6217939B2|2017-10-25|Bile acid reuse inhibitors for the treatment of hyperbileemia and cholestatic liver disease

---

US6369103B1|2002-04-09|Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor

同族专利:

---

公开号 | 公开日

---

AT241386T|2003-06-15|

---

CN1342089A|2002-03-27|

---

HU0201972A3|2005-06-28|

---

NO20013161D0|2001-06-22|

---

HK1044479A1|2002-10-25|

---

ES2200587T3|2004-03-01|

---

EP1342475A1|2003-09-10|

---

CA2356422A1|2000-07-06|

---

EA005815B1|2005-06-30|

---

HK1041443A1|2003-09-19|

---

US20030203892A1|2003-10-30|

---

IL143946D0|2002-04-21|

---

AU776620B2|2004-09-16|

---

CA2356422C|2008-09-16|

---

DE69908414T2|2004-04-01|

---

MXPA01006471A|2004-03-10|

---

DK1140188T3|2003-09-29|

---

HU0201972A2|2002-10-28|

---

WO2000038726A1|2000-07-06|

---

NZ512536A|2003-11-28|

---

EP1140188A1|2001-10-10|

---

EA200100705A1|2002-02-28|

---

PL348508A1|2002-05-20|

---

PT1140188E|2003-10-31|

---

DE69908414D1|2003-07-03|

---

JP2002533412A|2002-10-08|

---

CZ20012340A3|2001-11-14|

---

BR9916486A|2002-02-05|

---

AU2157800A|2000-07-31|

---

EP1140188B1|2003-05-28|

---

US6458851B1|2002-10-01|

---

NO20013161L|2001-08-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1998-12-23|Priority to US11395598P

---

1998-12-23|Priority to US60/113,955

---

1999-07-07|Priority to US14304799P

---

1999-07-07|Priority to US60/143,047

---

1999-12-17|Application filed by 윌리암스 로저 에이, 지.디. 썰 엘엘씨

---

1999-12-17|Priority to PCT/US1999/027947

---

2001-12-07|Publication of KR20010108046A

优先权:

---

申请号 | 申请日 | 专利标题

---

US11395598P| true| 1998-12-23|1998-12-23|

---

US60/113,955|1998-12-23|

---

US14304799P| true| 1999-07-07|1999-07-07|

---

US60/143,047|1999-07-07|

---

PCT/US1999/027947|WO2000038726A1|1998-12-23|1999-12-17|Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications|